Q-omics provides the consensus-scored PRPF31 profile across patient tissues and cancer cell-line models. PRPF31 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, PRPF31 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, PRPF31 protein abundance shows 29,235 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, KIRC, and GBM as cancer lineages where PRPF31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF31 survival associations across molecular data types. PRPF31 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF31 RNA expression–survival associations across cancer types. High PRPF31 expression shows unfavorable associations in LIHC, UVM, ACC, LGG and MESO, but favorable associations in SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for PRPF31 RNA expression.
This table summarizes PRPF31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRPF31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF31 shows higher tumor expression in KIRC, COAD, HNSC, LIHC, STAD and BLCA. The KIRC box plot shows higher PRPF31 RNA expression in tumor versus normal tissue (log2 FC = +0.511, t-test p < 0.001).
This table shows molecular features associated with PRPF31 in patient tissues and cancer cell lines. In patient samples, PRPF31 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRPF31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
